Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.50 |
| ▸ | KLK1 | P06870 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032709 | 0.83 | SELL (0.50) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL652876 | 0.80 | KDM4E (0.58) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL10495291 | 0.79 | ALDH1A1 (0.41) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| Hydrochloric Acid SCHEMBL1447901 | 0.78 | KDM4E (0.56) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL1544723 | 0.77 | PLAU (0.55) | ALDH1A1HPGDHSD17B10KLK1KLK5 | |
| SCHEMBL11097025 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL424097 | 0.76 | KDM4E (0.67) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL3743759 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| SCHEMBL29552052 | 0.76 | KDM4E (0.67) | ALDH1A1HPGDHSD17B10LMNAALOX15 | |
| Hydrochloric Acid SCHEMBL21553857 | 0.76 | ALB (0.53) | ALDH1A1ALOX15RECQLKLK1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114269340-A | KCNT1 inhibitors and methods of use | 普拉克西斯精密药物股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2019-05-07 | — | — | US | disclosed |
| CN-107108638-A | Piperidyl PyrazolopyrimidinonecGMP and application thereof | 拜耳制药股份公司 | 2017-08-29 | — | — | CN | disclosed |
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-08-03 | — | — | US | disclosed |
| CN-102993084-B | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMACEUTICALS SA | 2015-05-20 | — | — | CN | disclosed |
| CN-101321525-B | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors | HOFFMANN LA ROCHE | 2013-01-30 | — | — | CN | disclosed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-100567267-C | Aramidine derivative, salt thereof, and antifungal agent containing the same | TOYAMA CHEMICAL CO LTD (JP) | 2009-12-09 | — | — | CN | disclosed |
| EP-2046732-A1 | IMPROVEMENT OF THE BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co.KG (DE) | 2009-04-15 | — | — | EP | disclosed |
| CN-101321525-A | Heteroaryl substituted piperidine derivatives as L-CPT1 inhibitors | HOFFMANN LA ROCHE (CH) | 2008-12-10 | — | — | CN | disclosed |
| CN-101166726-A | Quinoline and quinoxaline derivatives as inhibitors of kinase enzyme activity | CHROMA THERAPEUTICS LTD (GB) | 2008-04-23 | — | — | CN | disclosed |
| WO-2008009264-A1 | IMPROVEMENT OF THE BIOAVAILABILITY OF ACTIVE SUBSTANCES HAVING AN AMIDINE FUNCTION IN MEDICAMENTS | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2008-01-24 | — | — | WO | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| CN-1976901-A | Novel arylamidine derivative, salt thereof, and antifungal containing these | TOYAMA CHEMICAL CO LTD (JP) | 2007-06-06 | — | — | CN | disclosed |
| WO-2007027878-A2 | 4-SUBSTITUTED 2-ARYLOXYPHENOL DERIVATIVES AS ANTIBACTERIAL AGENTS | EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-5366996-A | Administering hydroxamic acids | ELFORD HOWARD L (US) | 1994-11-22 | — | — | US | disclosed |
| US-5183828-A | Ribonucleotide reductase inhibitor and free radical scavenger | RIET BARTHOLOMEUS VAN T (US) | 1993-02-02 | — | — | US | disclosed |
| US-4942253-A | INHIBITORS OF RIBONUCLEOTIDE REDUCTASE, ANTITUMOR AGENTS, LEUKEMIA, FREE RADICAL SCAVENGERS | RIET BARTHOLOMEUS VAN T (US) | 1990-07-17 | — | — | US | disclosed |
| US-4623659-A | RIBONUCLEOTIDE REDUCTASE INHIBITORS | RIET BARTHOLOMEUS VAN T (US) | 1986-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170216293-A1 | THIENOPYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TYMS, TYMP, TPX2 | ALDH1A1 2065/4885HPGD 527/4885HSD17B10 4234/4885 |
| US-10278972-B2 | Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them | TYMS, TYMP, TPX2 | ALDH1A1 2065/4885HPGD 527/4885HSD17B10 4234/4885 |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | ALDH1A1 104/4885HPGD 1151/4885HSD17B10 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.